During the course of our investigations in the field of azole antimicrobial agents, we have identified BM212 a pyrrole derivative with good in vitro activity against mycobacteria and candidae. These findings prompted us to prepare new pyrrole derivatives 2–6 in the hope of increasing the activity. The microbiological data showed intersting in vitro activity against Mycobacterium tuberculosis and atypical mycobacteria.